Table 5.

Association between NAT2 phenotypes and risk of NHL and NHL subtypes.

	Slow*		Intermediate*			Rapid*				Intermediate/Rapid
	N(%)	OR(95% CI)**	N(%)	OR(95% CI)**	p	N(%)	OR(95% CI)**	p	p for linear trend	N(%)	OR(95% CI)**	p
Controls	452(55.9)		306(37.9)			50(6.2)					356(44.1)
All NHL	523(53.1)	1.00 (reference)	390(39.6)	1.18 (0.97, 1.44)	0.1	72(7.3)	1.44 (0.97, 2.14)	0.07	0.03	462(46.9)	1.21 (1.00, 1.47)	0.05
By NHL subtype
DLBCL	173(55.4)	1.00 (reference)	114(36.5)	1.05 (0.79, 1.39)	0.7	25(8.0)	1.52 (0.89, 2.58)	0.1	0.2	139(44.6)	1.11 (0.85, 1.45)	0.5
Follicular lymphoma	113(48.5)	1.00 (reference)	104(44.6)	1.50 (1.10, 2.04)	0.01	16(6.9)	1.52 (0.82, 2.82)	0.2	0.01	120(51.5)	1.50 (1.11, 2.02)	0.008
SLL	73(56.6)	1.00 (reference)	46(35.7)	1.02 (0.68, 1.52)	0.9	10(7.8)	1.58 (0.75, 3.31)	0.2	0.4	56(43.4)	1.08 (0.74, 1.59)	0.7
Marginal zone	37(45.1)	1.00 (reference)	44(53.7)	1.76 (1.10, 2.82)	0.02	1(1.2)	0.24 (0.03, 1.83)	0.2	0.4	45(54.9)	1.56 (0.98, 2.49)	0.06
All T-cell	36(63.2)	1.00 (reference)	18(31.6)	0.78 (0.43, 1.42)	0.4	3(5.3)	0.86 (0.25, 2.99)	0.8	0.5	21(36.8)	0.79 (0.45, 1.41)	0.4

^*NAT2 phenotypes: Slow (NAT2*5B/*6A, NAT2*5/*5, NAT2*5/*6, NAT2*5B/*5B, NAT2*5B/*7B, NAT2*6/*6, NAT2*6A/*6A, NAT2*5/*7, NAT2*5A/*5B, NAT2*5A/*5C, NAT2*5A/*6A, NAT2*5A/*7B, NAT2*5B/*5C, NAT2*5C/*6A, NAT2*5C/*7B, NAT2*6/*7, NAT2*6A/*7B, NAT2*7/*7, NAT2*7B/*7B); Intermediate (NAT2*4/*5, NAT2*4/*5B, NAT2*4/*6, NAT2*4/*6A, NAT2*4/*5A, NAT2*4/*5C, NAT2*4/*7, NAT2*4/*7B, NAT2*5B/*12A, NAT2*5B/*13, NAT2*5C/*12A, NAT2*6A/*12A, NAT2*6A/*13, NAT2*7B/*12A, NAT2*7B/*13); Rapid (NAT2*4/*4, NAT2*12A/*13, NAT2*4/*12A, NAT2*4/*13).

^**OR (95% CI) adjusted for age, sex, race, and study center.